Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BLUE 
Bluebird bio Inc (BLUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BLUE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -65.62% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 47.78M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 650534 | Beta 0.82 | 52 Weeks Range 3.56 - 28.60 | Updated Date 03/31/2025 |
52 Weeks Range 3.56 - 28.60 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -24.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -6.295 | Actual -2.84 |
Profitability
Profit Margin -287.23% | Operating Margin (TTM) -94.77% |
Management Effectiveness
Return on Assets (TTM) -31% | Return on Equity (TTM) -295.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 347330867 | Price to Sales(TTM) 0.61 |
Enterprise Value 347330867 | Price to Sales(TTM) 0.61 | ||
Enterprise Value to Revenue 4.14 | Enterprise Value to EBITDA -1.5 | Shares Outstanding 9790070 | Shares Floating 9724281 |
Shares Outstanding 9790070 | Shares Floating 9724281 | ||
Percent Insiders 0.71 | Percent Institutions 31.15 |
Analyst Ratings
Rating 3.1 | Target Price 26 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 6 | Sell 2 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bluebird bio Inc
Company Overview
History and Background
Bluebird bio Inc. was founded in 1992. Initially focused on gene therapy for hematologic disorders, it has evolved to develop therapies for severe genetic diseases. Significant milestones include FDA approvals for its gene therapies.
Core Business Areas
- Severe Genetic Diseases: Focuses on developing and commercializing transformative gene therapies for severe genetic diseases.
Leadership and Structure
The leadership team consists of Andrew Obenshain (CEO), Richard Colvin (CFO), and other key executives. The organizational structure is typical of a biotech company, with research, development, and commercialization divisions.
Top Products and Market Share
Key Offerings
- Zynteglo (betibeglogene autotemcel): A gene therapy approved for transfusion-dependent beta-thalassemia. Competing with supportive care and potential curative therapies like stem cell transplants. Revenue depends on adoption rates, currently limited. Market share is still evolving post-approval and faces challenges due to price and reimbursement hurdles.
- Skysona (elivaldogene autotemcel): A gene therapy approved for early, active cerebral adrenoleukodystrophy (CALD). Competitors include allogeneic hematopoietic stem cell transplantation (allo-HSCT). Revenue depends on adoption rates, currently limited. Market share is still evolving post-approval and faces challenges due to the risk/benefit profile.
- Lyfgenia (lovotibeglogene autotemcel): A gene therapy approved for sickle cell disease. Competitors include stem cell transplant and other disease modifying therapies like Oxbryta (voxelotor) from Global Blood Therapeutics (GBT, acquired by Pfizer).
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by technological advancements and increasing success rates in clinical trials. It's characterized by high development costs, complex regulatory pathways, and significant pricing pressures.
Positioning
Bluebird bio is a pioneer in gene therapy, with a focus on hematologic disorders and severe genetic diseases. Its competitive advantage lies in its established platform and clinical data, but it faces challenges related to pricing and market access.
Total Addressable Market (TAM)
The TAM for gene therapies is estimated to be in the tens of billions of dollars. Bluebird bio is positioned to capture a portion of this market with its approved therapies, but faces competition and reimbursement challenges.
Upturn SWOT Analysis
Strengths
- Pioneering gene therapy platform
- FDA-approved gene therapies
- Strong scientific expertise
- Focus on rare genetic diseases
Weaknesses
- High cost of goods
- Pricing and reimbursement challenges
- Limited manufacturing capacity
- History of regulatory setbacks
Opportunities
- Expanding gene therapy pipeline
- Partnerships and collaborations
- Geographic expansion
- New indications for existing therapies
Threats
- Competition from other gene therapy companies
- Regulatory hurdles
- Reimbursement challenges
- Potential safety concerns
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
Competitive Landscape
Bluebird bio faces competition from other gene therapy companies, as well as established pharmaceutical companies with alternative treatments for its target diseases. Its advantages include its pioneering platform and clinical data, but it faces challenges related to pricing and market access.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been marked by periods of significant investment in R&D, clinical trials, and regulatory approvals. Revenue growth has been limited due to the nascent nature of its commercial products.
Future Projections: Future growth is dependent on successful commercialization of approved therapies, expansion of the pipeline, and securing favorable reimbursement terms. Analyst projections vary widely.
Recent Initiatives: Recent initiatives include focusing on commercializing approved therapies, streamlining operations, and seeking partnerships to expand access to its products.
Summary
Bluebird bio is a pioneer in gene therapy with approved treatments for severe genetic diseases, however, they face significant challenges. These challenges include high costs, pricing/reimbursement hurdles, and competition. They need to successfully commercialize their products and address manufacturing capacity to realize their growth potential. Overcoming pricing and reimbursement challenges is critical to their success.
Similar Companies
BEAM
Beam Therapeutics Inc
BEAM
Beam Therapeutics Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is rapidly changing as they grow. It is best to check recent fillings for most up-to-date information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bluebird bio Inc
Exchange NASDAQ | Headquaters Somerville, MA, United States | ||
IPO Launch date 2013-06-19 | President, CEO & Director Mr. Andrew Obenshain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 248 | Website https://www.bluebirdbio.com |
Full time employees 248 | Website https://www.bluebirdbio.com | ||
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.